Table 4 Nonhistone acetylation in hypoxia.
Name | Substrate | Effect | Cell type (cell line) | O2 (%) | Ref. |
|---|---|---|---|---|---|
Histone acetyltransferases | |||||
P300/CBP | HIF-1α K709 | Increase in HIF-1α stability | Embryonic kidney cell (HEK293T) | 1 | |
Glioblastoma (LN229) | |||||
PCAF | HIF-1α K674 | Increase in HIF-1α stability | Fibrosarcoma (HT1080) | 1 | |
ELP3 | PAK1 K420 | Inhibition of PAK1 dimerization leading to enhanced PAK1 activity | Glioblastoma (LN229) | Not specified | |
MYST1 | N-terminal of HIF-1α | Decrease in HIF-1α stability | Hepatocellular carcinoma (Huh-7, Hep3B) | CoCl2 | |
Histone deacetylases | |||||
HDAC2 | HIF-1α K532 | Increase in HIF-1α stability | Oral squamous cell carcinoma (HSC-3) | Not specified | |
HDAC3 | P-TEFb | Inhibition of transcription elongation | Cervical cancer (HeLa) | 0.5 | |
HDAC4 | K10, K11, K12, K19, and K21 of HIF-1α | Increase in HIF-1α stability | Hepatocellular carcinoma (Hep3Bc1), Prostate cancer (C42B) | 1 | |
HDAC5 | HSP70 | Increase in mature HIF-1α accumulation | Hepatocellular carcinoma (Hep3B), cervical cancer (HeLa) | 1 | |
HDAC6 | HSP70 | Increase in HIF-1α stability and transactivity in a VHL-independent manner | Embryonic fibroblast (MEF) | 1 | |
Lung cancer (A549) | 1 | ||||
Renal cell carcinoma (UMRC2) | (CoCl2) | ||||
SIRT1 | HIF-1α K674 | Suppression of HIF-1α target gene | Fibrosarcoma (HT1080) | 1 | |
Renal proximal tubule cell (HK2) | Â | ||||
SIRT1 | HIF-2α K385, K685, and K741 | Activation of HIF-2α transactivity | Hepatocellular carcinoma (Hep3B) | 1 | |
SIRT2 | HIF-1α K709 | Decrease in HIF-1α stability (Induction of HIF-1α degradation) | Cervical cancer (HeLa) | 1 | |
B cell precursor leukemia (NALM-6) | Â | ||||
SIRT3 | FOXO3 | Inhibition of FOXO3 degradation | Endothelial cell (HUVEC) | 2 | |
